Stahl SM. Personalized Medicine, pharmacogenomics and the practice of psychiatry: on the threshold of predict therapeutics in psychopharmacology?
CNS Spectr. 2008; 13(2): 115–118.
Mrazek DA. Psychiatric Pharmacogenomics. New York: Oxford University Press; 2010.
Bousman CA. Commercial pharmacogenomics-based decision support tools in psychiatry. Lancet Psychiatry. 2016; 3(6): 585–590.
Braff DL, Freedman R. Clinically responsible genetic testing in neuropsychiatric patients: a bridge too far and too soon. Am J Psychiatry. 2008; 165(8): 952–955.
Malhotra AK, Murphy GM, Kennedy JL. Pharmacogenetics of psychotropic drug response. Am J Psychiatry. 2004; 161(5): 780–796.
Cross-Disorder Group of the Psychiatric Genomics Consortium. Identification of risk loci with shared effects on five major psychiatric disorders: a genome wide analysis. Lancet. 2013; 381(9875): 1371–1379.
Lotrich FE. The emerging potential of pharmacogenetics in psychiatry. Am J Psychiatry. 2012; 169(7): 681–683.
Beevers CG, McGeary JE. Therapygenetics: moving towards personalized psychotherapy treatment. Trends Cogn Sci. 2012; 16(1): 11–12.
Falcone M, Smith RM, Chenoweth MG, et al. Neuroimaging in psychiatric pharmacogenetics research: the promise and the pitfalls. Neurospsychopharmacology. 2013; 38(12): 2327–2337.
Varela MA, Roberts TC, Wood MJA. Epigenetics and ncRNAs in Brain Function and Disease: mechanisms and prospects for therapy. Neurotherapeutics. 2013; 10(4): 621–631.
Perlis RH. Can single genes matter in a polygenic world?
Biol Psychiatry. 2010; 68(9): 783–784.
Caspi A, Hariri AR, Holmes A, Uher R, Moffitt TE. Genetic sensitivity to the environment: the case of the serotonin transporter gene and its implications for studying complex diseases and traits. Am J Psychiatry. 2010; 167(5): 509–527.
Niculescu AB, Levey D, Le-Niculescu H, Niculescu E, Kurian SM, Salomon D. Psychiatric mood biomarkers: avoiding jumping to premature negative or positive conclusions. Mol Psychiatry. 2015; 20(3): 286–288.
Stahl SM. The last Diagnostic and Statistical Manual (DSM): replacing our symptom-based diagnoses with a brain circuit-based classification of mental illnesses. CNS Spectr. 2013; 18(2): 65–68.
Stahl SM. Stahl’s Essential Psychopharmacology. 4th ed. New York: Cambridge University Press; 2014.
Morrissette DA, Stahl SM. Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy. CNS Spectr. 2014; 19(5): 439–448.
Stahl SM, Morrissette DA, Cummings M, et al. California State Hospital Violence Assessment and Treatment (Cal-VAT) guideline. CNS Spectr. 2014; 19(5): 449–465.
Ruaño G, Szarek BL, Villagra D, et al. Length of psychiatric hospitalization is correlated with CYP2D6 functional status in inpatients with major depressive disorder. Biomark Med. 2013; 7(3): 429–439.
Herbild L, Andersen SE, Werge T, Rasmussen HB, Jürgens G. Does pharmacogenetic testing for CYP450 2D6 and 2C19 among patients with diagnoses within the schizophrenic spectrum reduce treatment costs?
Basic Clin Pharmacol Toxicol. 2013; 113(4): 266–272.
Brennan FX, Gardner KR, Lombard J, et al. A naturalistic study of the effectiveness of pharmacogenetic testing to guide treatment in psychiatric patients with mood and anxiety disorders. Prim Care Companion CNS Disord. 2015; 17(2). doi: 10.4088/PCC.14m01717.
Fagerness J, Fonesca E, Hess GP, et al. Pharmacogenetic-guided psychiatric intervention associated with increased adherence and cost savings. Am J Manag Care. 2014; 20(5): e146–e156.
Hall-Flavin DK, Winner JG, Allen JD, et al. Using a pharmacogenomic algorithm to guide the treatment of depression. Transl Psychiatry. 2012; 2: e172.
Hall-Flavin DK, Winner JG, Allen JD, et al. Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenet Genomics. 2013; 23(10): 535–548.
Winner JG, Carhart JM, Altar CA, Allen JD, Dechairo BM. A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder. Discov Med. 2013; 16(89): 219–227.